A case series of cefixime induced Steven’s Johnson Syndrome
Keywords:Cefixime, Hypersensitivity reactions, Stevens-Johnson syndrome
Drug induced adverse reactions are a major health problem. Drug hyper sensitivity reactions manifest themselves in many diseases, of which some are very severe. The most common allergic reactions occur in the skin. Stevens-Johnson syndrome is mainly caused by drugs (antimicrobials e.g.: penicillin’s, sulphonamides and cephalosporin’s e.g.: cefixime, antiepileptic’s, NSAIDS), infections and also by other risk factors not yet identified. The most common allergic reactions occur in the skin. These reactions ranging from simple pruritic eruptions to potentially life threatening events are a significant cause of iatrogenic morbidity and mortality. Identification of the cause, withdrawal of the trigger and supportive management is crucial to improve the patient state. Despite of all therapeutic efforts, mortality is high and increases with disease severity, patient’s age and underlying medical conditions. Survivors may suffer from long-term squeal such as strictures of mucous membranes including severe eye problems.
Finkelstein Y, Macdonald EM, Li P, Hutson JR, Juurlink DN. Recurreenece and mortality following severe cutaneous reactions. JAMA. 2014 Jun 4;311(21):2231-2.
Tan SK, Tay YK. Profile and pattern of Stevens-Johnson syndrome and toxic epidermal necrolysis in a general hospital in Singapore: treatment outcomes. Actadermato-venereolgica. 2012 Jan 1;92(1):62-6.
Lee HY, Tharmotharampillai T, Pang SM. Recurrence of Stevens - Johnson syndrome and toxic epidermal necrolysis in adults. Int J Dermatol. 2017 Apr 1;56(4).
Nappe TM, Goren-Garcia SL, Jacoby JL. Stevens-Johnson syndrome after treatment with azithromycin: an uncommon culprit. The American journal of emergency medicine. 2016 Mar 1;34(3):676-e1.
Patel TK, Barvaliya MJ, Sharma D, Tripathi C. A systematic review of the drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Indian population. Ind J Dermatol Venereol Leprol. 2013 May1;79(3):389.
Frey N, Jossi J, Bodmer M, Bircher A, Jick SS, Meier CR, et al. The epidemiology of Stevens-Johnson syndrome and toxic epidermal necrolysis in the UK. J Investig Dermatol. 2017 Jun 1;137(6):1240-7.
Wen-Hung C, Shuen-lu H. Recent advances in the genetics and immunology of Stevens-Johnson syndrome and toxic epidermal necrosis. J Dermatol Scien. 2012;66:190-6.
Jain R, Sharma N, Basu S, Iyer G, Ueta M, Sotozono C, et al.Stevens-Johnson syndrome: The role of an ophthalmologist. Surv Ophthalmol. 2016;61:369-99.
Schwartz RA, McDonough PH, Lee BW. Toxic epidermal necrolysis: Part II. Prognosis, sequelae, diagnosis, differential diagnosis, prevention and treatment. J Am Acad Dermatol. 2013;69(2):187.e1-16.
Mockenhaupt M. Stevens-Johnson syndrome and toxic epidermal necrolysis: clinical patterns, diagnostic considerations, etiology, and therapeutic management. Semin Cutan Med Surg. 2014;33(1):10-6.
Yang MS, Lee JY, Kim J, Kim GW, Kim BK, Kim JY, et al. Incidence of Stevens-Johnson Syndrome and toxic epidermal necrolysis: a nationwide population-based study using National Health Insurance database in Korea. PloS one. 2016 Nov 11;11(11):e0165933.
Harr T, French LE. Stevens - Johnson syndrome and Toxic Epidermal Necrolysis French LE (ed): Adverse Cutaneous Drug Eruptions. Chem Immunol Allergy. Basel, Karger. 2012;97:149-66.
Belver MT, Michavila A, Bobolea I, Feito M, Bellón T, Quirce S. Severe delayed skin reactions related to drugs in the paediatric age group: a review of the subject by way of three case (Stevens-Johnson syndrome, toxic epidermal and DRESS). Allergol Immunopathol (Madr). 2016;44:83-95.
Bentley, John: Sie, David. Stevens-Johnson syndrome and toxic epidermal necrolysis. Pharmace J. October 2014;293(7832).
Maverakis E, Wang EA, Shinkai K, Mahasirimongkol S, Margolis DJ, Avigan M, et al. Stevens-Johnson Syndrome and toxic epidermal necrolysis standard reporting and evaluation guidelines: results of a National Institutes of Health working group. JAMA dermatology. 2017 Jun 1;153(6):587-92.
UK Antibiotic Research. New research reveals that antibiotic prescriptions are rising in the most deprived areas of England; 2015. Available at: http://www.antibioticresearch.org.uk/wp-content/uplods/2015/11/EXASOL-Anaiyses_Antibiotic-Research-UK-Final-121115.pdf;2015(accessed 27 Feb 2017)
Wen-Hung C, Shuen-lu H. Genetic Markers and Danger Signals in Stevens - Johnson syndrome and Toxic Epidermal Necrolysis. Japanese Society of Allergology. 2010;59:325-32.
Ovivera OA, Sanches M, Selores M. [Stevens-Johnson syndrome and toxic epidermal necrolysis]. Acta Med Port. 2011;24(4):995-1002.
Schulte W, Bernhagen J, Bucala R. Cytokines in sepsis: potent immunoregulators and potential therapeutic targets- an updated view. Mediators Inflamm. 2013;2013:165974.
Chantaphakul H, Sanon T, Klaewsongkram J. Clinical chareceristics and treatment outcome of Stevens-Johnson syndrome and toxic epidermal necrolysis. Experimental and therapeutic medicine. 2015 Aug 1;10(2):519-24.
Fujita Y, Yoshioka N, Abe R, Murata J, Hoshina D, Mae H, et al. Rapid immunochromatographic test for serum granulysin is useful for the prediction of Stevens-Johnson syndrome and toxic epidermal necrolysis. J Ame Acade of Dermatol. 2011 Jul 1;65(1):65-8.
Su SC, Mockenhaupt M, Wolkenstein P, Dunant A, Le Gouvello S, Chen CB, et al. Interleukin-15 is associated with severity and mortality in Stevens-Johnson syndrome/toxic epidermal necrolysis. J Investiga Dermatol. 2017 May 1;137(5):1065-73.
Robert S. Stern and Sherrie J. Divito Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: Associations, Outcomes, and Pathobiology- Thirty Years of Progress but Still Much to Be Done. J Investiga Dermatol. 2017;137:1004e-1008e.
Su SC, Chung WH. Update on pathobiology in Stevens-Johnson syndrome and toxic epidermal necrolysis. Dermatol Sin. 2013;31:175e80.
Thong BY. Stevens-Johnson syndrome / toxic epidermal necrolysis: an Asia- Pacific perspective. Asia Pac Allergy. 2013;3(4):215-23.
Mawson AR, Eriator I, Karre S. Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS/TEN): could retinoids play a causative role? Med Sci Monit. 2015;21:133-43.
Bansal S, Garg VK, Sardana K, Sarkar R. A clinicotherapeutic analysis of Stevens‑Johnson syndrome and toxic epidermal necrolysis with an emphasis on the predictive value and accuracy of SCORe of toxic epidermal necrolysis. Int J Dermatol. 2015;54:e18‑26.
Thong BY, Mirakian R, Castells M, Pichler W, Romano A, Bonadonna P, et al. A world allergy organization international survey on diagnostic procedures and therapies in drug allergy/hypersensitivity. World Allergy Organ J. 2011;4:257‑70.
Chung WH, Chang WC, Stocker SL, Juo CG, Graham GG, Lee MH, et al. Insights into the poor prognosis of allopurinol-induced severe cutaneous adverse reactions: the impact of renal insufficiency, high plasma levels of oxypurinol and granulysin. Ann Rheum Dis. 2015;74:2157e64.
Morel E, Escamochero S, Cabañas R, Díaz R, Fiandor A, Bellón T. CD94/NKG2C is a killer effector molecule in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis. Journal of Allergy and Clinical Immunology. 2010 Mar 31;125(3):703-10.
The use of the WHO-UMC system for standardized case causality assessment. Available at: http://who-mc.org/Graphics/24734.pdf.
Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactoins. Clin Pharmacol Ther. 1981;30:239-45.
Fernando SL. The management of toxic epidermal necrolysis. Australas J Dermatol. 2012; 53(3):165-71.
Lee HY, Dunant A, Sekula P, Mockenhaupt M, Wolkenstein P, Valeyrie‑Allanore L, et al. The role of prior corticosteroid use on the clinical course of Stevens‑Johnson syndrome and toxic epidermal necrolysis: A case‑control analysis of patients selected from the multinational Euro SCAR and Regi SCAR studies. Br J Dermatol. 2012;167:555‑62.
Roongpisuthipong W, Prompongsa S, Klangjareonchai T. Retrospective analysis of corticosteroid treatment in Stevens-Johnson syndrome and/or toxic epidermal necrolysis over a period of 10 years in Vajira Hospital, Navamindradhiraj University, Bangkok. Dermatology research and practice. 2014;2014.